Dr. Mason is Director of the Cancer Imaging Program at UT Southwestern with over 20 year's experience in cancer imaging, therapy, and tumor pathophysiology. He is Professor of Radiology and member of the Simmons Comprehensive Cancer Center. He serves on faculty of graduate programs in Biomedical Engineering, Molecular Biophysics and Cancer Biology. Dr. Mason and his research team have been supported for many years by NCI, DOD breast and prostate cancer initiatives, various foundations including The American Cancer Society, The Whitaker Foundation, and The Mary Kay Ash Foundation and most recently CPRIT. Dr. Mason’s primary research interest is prognostic radiology- developing and implementing methods for predicting optimal cancer therapy and assessing early response to treatment. Current investigations focus on development of oxygen sensitive MRI in pre-clinical breast, prostate and lung cancer as well as translation to human lung and prostate cancer. Dr. Mason is a recognized expert in the development of novel MR and optical reporter starategies with notable innovations in 19F NMR. Recent pre-clinical innovations include dynamic bioluminescent imaging related to vascular disputing agents and in vivo chemiluminescent imaging. Ongoing projects focus on novel vascular disrupting agents and assessment of pathophysiology of tumor response to therapy.
- University of Cambridge (1983), Natural Sciences
- Graduate School
- University of Cambridge (1986), Organic Chemistry
- Application of imaging methods to tumor development and response to therapy; development of NMR reporter molecules as probes of physiology and gene transfection; detoxification of xenobiotica; MR miscroscopy and tissue microstructure.
- Bioluminescent imaging
- gene therapy
- NMR- MRI
- Developing oxygen-enhanced magnetic resonance imaging as a prognostic biomarker of radiation response.
- White DA, Zhang Z, Li L, Gerberich J, Stojadinovic S, Peschke P, Mason RP Cancer Lett. 2016 Jun 380 1 69-77
- A role for dynamic contrast-enhanced magnetic resonance imaging in predicting tumour radiation response.
- Hallac RR, Zhou H, Pidikiti R, Song K, Solberg T, Kodibagkar VD, Peschke P, Mason RP Br. J. Cancer 2016 May 114 11 1206-11
- Dynamic oxygen challenge evaluated by NMR T1 and T2 * - insights into tumor oxygenation.
- Zhao D, Pacheco-Torres J, Hallac RR, White D, Peschke P, Cerdán S, Mason RP NMR Biomed 2015 Jun
- Evaluation of tumor ischemia in response to an indole-based vascular disrupting agent using BLI and (19)F MRI.
- Zhou H, Hallac RR, Lopez R, Denney R, MacDonough MT, Li L, Liu L, Graves EE, Trawick ML, Pinney KG, Mason RP Am J Nucl Med Mol Imaging 2015 5 2 143-53
- Correlations of noninvasive BOLD and TOLD MRI with pO2 and relevance to tumor radiation response.
- Hallac RR, Zhou H, Pidikiti R, Song K, Stojadinovic S, Zhao D, Solberg T, Peschke P, Mason RP Magn Reson Med 2013 Jun
- New frontiers and developing applications in (19)F NMR.
- Yu JX, Hallac RR, Chiguru S, Mason RP Prog Nucl Magn Reson Spectrosc 2013 Apr 70 25-49
- Oxygenation in cervical cancer and normal uterine cervix assessed using blood oxygenation level-dependent (BOLD) MRI at 3T.
- Hallac RR, Ding Y, Yuan Q, McColl RW, Lea J, Sims RD, Weatherall PT, Mason RP NMR Biomed 2012 Dec 25 12 1321-30
- A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.
- Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG Integr Biol (Camb) 2011 Apr 3 4 375-87
- Carbon ion radiotherapy decreases the impact of tumor heterogeneity on radiation response in experimental prostate tumors.
- Glowa C, Karger CP, Brons S, Zhao D, Mason RP, Huber PE, Debus J, Peschke P Cancer Lett. 2016 Aug 378 2 97-103
- Effective Rat Lung Tumor Model for Stereotactic Body Radiation Therapy.
- Zhang Z, Wodzak M, Belzile O, Zhou H, Sishc B, Yan H, Stojadinovic S, Mason RP, Brekken RA, Chopra R, Story MD, Timmerman R, Saha D Radiat. Res. 2016 Jun 185 6 616-22
19F NMR: clinical and molecular imaging applications. In Fluorine in Pharmaceutical and Medicinal Chemistry: From Biophysical Aspects to Clinical Applications
V. D. Kodibagkar, R. Hallac, D. Zhao, J.-X. Yu, and R. P. Mason (2012). London, World Scientific Publishing Company
Non-Invasive Physiology and Pharmacology Using 19F Magnetic Resonance. In FLOURINE AND HEALTH
J.X. Yu, W. Cui, D. Zhao, and R. P. Mason (May 2008). Elsevier B.V.
Fluorocarbon Agents for Quantitative Multimodal Molecular Imaging and Targeted Therapeutics. In Molecular Imaging: Principles and Practice
S. A. Wickline, R. P. Mason, S. D. Caruthers, J. Chen, P. M. Winter, M. S. Hughes, G. M. Lanza (2010). People?s Medical Publishing House
MRI Hypoxia Measurements. In Functional Imaging in Oncology
S. Remmele, R. P. Mason, and J. P.B. O?Connor (2014). Heidelberg, Springer-Verlag
Innovative applications of reporter genes and gene reporters in prostate cancer. In Prostate Cancer Cells: Detection, Growth and Treatment
L. Liu, M. K. Alhasan, W. Cui, J. Magnusson, and R. P. Mason (2013). Hauppauge, NY, Nova Science Publishers
Honors & Awards
- Visiting Professor to the Hubei University of Medicine (HUM)
Famous Scientists Lecture Program in Hubei Province (2015-2015)
- Fellow of Royal Society of Chemistry
Chartered Scientist designation of the Science Council (2004)
- Lyndon Baines Johnson Award
American Heart Association (Texas Affiliate) (1993)
- Young Investigator Award at 5th International Society of Blood Substitutes Meeting
Presentation: Tumor oxygen tension: Measurement using OxygentTM as a 19F NMR probe at 4.7 T (1993)
Chartered Chemist of the Royal Society of Chemistry (1987)
- American Journal of Nuclear Medicine and Molecular Imaging (2011)
- Imaging in Medicine (2009)
- Letters in Drug Design & Discovery (2005)
- American Association for Cancer Research (1993)
- International Society of Magnetic Resonance in Medicine (1990)
- Royal Society of Chemistry (1987)